-
1 Comment
From a valuation standpoint, the stock is 86.6% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 23.9.
Based on the above factors, Lexaria Bioscience Corp gets an overall score of 1/5.
Industry | Biotechnology |
---|---|
Sector | Healthcare |
ISIN | US52886N4060 |
CurrencyCode | USD |
Exchange | NASDAQ |
Beta | 1.12 |
---|---|
Dividend Yield | 0.0% |
Target Price | 15 |
PE Ratio | None |
Market Cap | 14M |
Lexaria Bioscience Corp. operates as a biotechnology company. It operates through two segments, Intellectual Property Licensing and B2B Production. The company develops and out-licenses its DehydraTECH technology that improves the delivery of bioactive compounds that promotes healthy ingestion methods, lowers overall dosing, and higher effectiveness in active molecule delivery. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and various cannabinoids. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 27 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LEXX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024